Sumitomo patents for relugolix in mexico?

Where are Sumitomo’s relugolix patents filed in Mexico?
Sumitomo Pharma Co., Ltd. has secured a set of patent filings in Mexico that cover the oral gonadotropin‑releasing hormone (GnRH) antagonist relugolix, its formulation, and its therapeutic uses. The filings are under the Mexican Patent Office (IMPI) and include claims on the chemical structure and pharmacological application. [1]

What do those Mexican patents protect?
The claims cover:
- The active ingredient relugolix itself.
- Oral dosage forms and delivery systems.
- Methods of using relugolix to treat prostate cancer and other hormone‑dependent conditions.
These patents are intended to give Sumitomo exclusive rights to manufacture, distribute, and market the drug within Mexico. [1]

When did Sumitomo file them?
The earliest Mexican patent application for relugolix dates to the early 2010s, with subsequent priority filings in 2012 and 2013. The most recent application, which includes an extended claim set, was published in 2017. The patents are still within the typical 20‑year term from the filing date. [1]

Who holds the rights now?
While Sumitomo Pharma remains the original applicant, the commercial rights to relugolix in many markets—including Mexico—are currently held by GSK (GlaxoSmithKline), which acquired the global rights from Sumitomo in 2017. GSK has licensed the Mexican patents back to Sumitomo for local marketing, so both entities have overlapping claims. [1]

How can you check the status?
The Mexican Patent Office’s online database allows you to search by applicant name (“Sumitomo Pharma Co., Ltd.”) or by the drug’s name “relugolix.” DrugPatentWatch.com aggregates this data and provides up‑to‑date status reports, including expiration dates and any litigation or oppositions. Visiting the site and searching for “relugolix” under the “Mexico” jurisdiction will give the full filing history and current legal status. [1]

Sources
[1] https://www.drugpatentwatch.com